Document:

Agreement between Registrant and American BioScience

 Exhibit 10.25 
  
 AGREEMENT  
  
 THIS AGREEMENT (this “Agreement”) is entered into as of March 11, 2004 between AMERICAN BIOSCIENCE, INC., a
California corporation (“ABI”), and AMERICAN PHARMACEUTICAL PARTNERS, INC., a Delaware corporation (“APP”). 
  
 RECITALS 
  

A.    ABI has developed and owns the rights to the Product (as defined below). 
  
 B.    In November 2001, ABI and APP entered into (i) a
License Agreement, pursuant to which ABI licensed to APP certain marketing and distribution rights in North America relating to ABI-007 (the “License Agreement”) and (ii) a Manufacturing Agreement, pursuant to which the parties agree that
APP would manufacture the Product. 
  
 C.    Although the Product has not yet been approved for sale by the FDA, each of ABI and APP have previously determined that it is in the bests interests of such company and its shareholders for APP to begin
accumulation of raw material inventory, manufacture certain quantities of Product and perform other activities relating to ABI-007, subject to a sharing of the costs of unsaleable Ramp-Up Inventory (as defined below) in the manner described herein.

  
 AGREEMENT 
  
 NOW, THEREFORE, in consideration of the premises, the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 
  
 1.    Definitions. Unless otherwise defined herein, the capitalized terms used in this Agreement
shall have the meanings assigned to such terms in this Section 1. All other capitalized terms used herein shall have the meaning assigned to such terms in the License Agreement. 
  
 “ABI Repayment Amount” shall mean 50% of the difference of (i) the Ramp-Up Inventory Reserve, less (ii)
twice the total Sums Previously Repaid by ABI.  
  
 “Demand Notice” shall have the meaning assigned to such term in Section 2. 
  

 1 

 “FDA” means the United States Food and Drug Administration or any other successor agency
whose approval is necessary to market the Product in the United States. 
  
 “NDA” means one or more of the New Drug Applications that ABI files for the Product with the FDA. 
  
 “Product” means ABI-007, a cremaphor-free, nanoparticle paclitaxel formulation: (A) as it is described in IND No. 55,974 and the
investigator’s brochure that relates to that IND, to be administered by intravenous injection for oncology indications; and (B) to be administered by intra-arterial injection, as may be developed by or on behalf of ABI, for oncology
indications. 
  
 “Ramp-Up Inventory” shall mean
APP’s inventories of or relating to the Product, including raw materials            , work in progress and finished goods. 
  
 “Ramp-Up Inventory Reserve” shall mean the aggregate expense (as reflected on APP’s financial
statements) incurred by APP prior to the date of the Demand Notice which is attributable to write-offs of any Ramp-Up Inventory as being unsaleable, all computed according to APP’s usual and standard accounting policies and GAAP. 
  
 “Sums Previously Repaid by ABI” shall mean any amounts paid
under and pursuant to this Agreement by ABI to APP prior to the date of any Demand Notice. 
  
 “Trigger Date” shall mean the earlier to occur of (i) the termination of the License Agreement and/or the Manufacturing Agreement or (ii)
30 days following any quarter end at which the ABI Repayment Amount exceeds $500,000. 
  
 2.    Payment by ABI. 
  
 a. At any time after the Trigger Date (but not after the date on which FDA approves the Product for any indication in the United States), APP may in its sole and absolute discretion deliver to ABI a written notice
(the “Demand Notice”) requesting that ABI pay to APP the ABI Repayment Amount. 
  
 b. Within 30 days after delivery of the Demand Notice, ABI shall pay to APP, by wire transfer or immediately available funds, the ABI Repayment Amount. 
  
 c. If ABI fails timely to pay in full the ABI Repayment Amount, then, without limiting any other rights and remedies of APP
under this Agreement or applicable law, ABI shall surrender to APP shares of APP common stock having a fair market value equal to 120% of the ABI Repayment Amount. 
  

 2 

 3.     Mitigation. Each party shall use reasonable commercial efforts within
the bounds of law and good practice to mitigate losses in respect of Ramp-Up Inventory for which ABI has made payments pursuant to this Agreement (e.g., special sales, donations to charity, use in on-going clinical trials or other development work),
and the parties shall equally share the benefit received in respect of such efforts (with payments or credits being made as applicable). 
  
 4.     Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the internal
substantive laws (and not the laws of conflicts) of the State of California. 
  
 5.     Entire Agreement. This Agreement constitutes the whole agreement of the parties hereto in reference to any of the matters or things herein provided for or hereinabove discussed all
prior agreements, promises, representations and understandings relative thereto being herein merged. 
  
 6.     Amendments; Waivers. This Agreement may be amended, modified, superseded, canceled, renewed or extended and the terms or
covenants of this Agreement may be waived only by a written instrument executed by the parties to this Agreement or, in the case of a waiver, by the party waiving compliance. The failure of any party at any time or times to require performance of
any provision of this Agreement shall in no manner affect the right at a later time to enforce the same. No waiver by any party of the breach of any term or provision contained in this Agreement, whether by conduct or otherwise, in any one or more
instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement. 
  
 7.     Severability. Any provision of this Agreement that is prohibited or unenforceable in any
jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction. 
  
 8.     Headings. The headings of the Sections and paragraphs of this Agreement have been inserted for convenience of reference only and do not constitute a part of this Agreement.

  
 9.     Attorneys’ Fees. If
either party to this Agreement seeks to enforce his or its rights under this Agreement, the prevailing party shall be entitled to recover reasonable fees, costs and expenses incurred in connection therewith including, without limitation, the fees,
costs and expenses of attorneys, accountants and experts, whether or not litigation is instituted, and including such fees, costs and expenses of appeals. 
  
 10.     Arbitration and Equitable Relief. The provisions of Section 33 of the License Agreement shall apply to any disputes or
controversies arising out of or relating to this Agreement. 
  

 3 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first indicated above.

  

			
	 AMERICAN BIOSCIENCE, INC.

		
	 By:
	 	 /s/ Patrick Soon-Shiong

		
	 Its:
	 	 CEO

  
  

			
	 AMERICAN PHARMACEUTICAL PARTNERS, INC.

		
	 By:
	 	 /s/ Nicole S. Williams

		
	 Its:
	 	 EVP & CFO

  

 4SERIES TERM CERTIFICATE

  
 Exhibit 4(a) 
  
 WAL-MART STORES, INC. 
  
 Series Terms Certificate 
 Pursuant to Section 3.01 of the Indenture 
  
 Pursuant to Section 3.01 of the Indenture, dated as of December 11, 2002 (the “Indenture”), made between Wal-Mart Stores, Inc., a Delaware
corporation (the “Company”) and J.P. Morgan Trust Company, National Association, as successor in interest to Bank One Trust Company, National Association, as Trustee (the “Trustee”), Joseph J. Fitzsimmons, Senior Vice President
of Finance and Treasurer of the Company, hereby certifies as follows, and Anthony D. George, Assistant General Counsel, Finance and Assistant Secretary of the Company, attests to the following certification. Any capitalized term used herein shall
have the definition ascribed to that term as set forth in the Indenture unless otherwise defined herein. 
  
 A. This certificate is a Series Terms Certificate contemplated by Section 3.01 of the Indenture and is being executed to evidence the establishment and
approval of the terms and conditions of the Series that was established pursuant to Section 3.01 of the Indenture by means of a Unanimous Written Consent of the Executive Committee of the Board of Directors of the Company, dated as of February 10,
2004 (the “Original Series Consent”), which Series is designated as the “4.125% Notes Due 2011” (the “2011 Series”), by Joseph J. Fitzsimmons, Senior Vice President of Finance and Treasurer of the Company, pursuant to
the grant of authority under the terms of the Original Series Consent. 
  
 B. Each of the undersigned has read the Indenture, including the provisions of Sections 1.02 and 3.01 and the definitions relating thereto, and the resolutions adopted in the Original Series Consent. In the opinion of the undersigned, the
undersigned have made such examination or investigation as is necessary to enable the undersigned to express an informed opinion as to whether or not all conditions precedent provided for in the Indenture relating to the execution and delivery by
the Trustee of the Indenture, to the creation, establishment and approval of the title, the form and the terms of a Series under the Indenture, and to the authentication and delivery by the Trustee of promissory notes of a Series, have been complied
with. In the opinion of the undersigned, (i) all such conditions precedent have been complied with and (ii) there are no Events of Default (as defined in the Indenture), or events which, with the passage of time, would become an Event of Default
under the Indenture. 
  
 C. Pursuant to the Original Series
Consent, the Company is authorized to issue $1,250,000,000 aggregate principal amount of promissory notes of the 2011 Series (the “Initial Notes”). A copy of the Original Series Consent is attached hereto as Annex A. Any promissory
notes that the Company issues that are a part of the 2011 Series (the “Notes”) shall be represented by one or more global securities substantially in the form attached hereto as Annex B (the “Form of Note”). 
  
 D. Pursuant to Section 3.01 of the Indenture, the terms and conditions of the
2011 Series and the promissory notes forming a part of the 2011 Series, including the Notes, are established and approved to be the following: 
  
  

  

	 	1.	Designation: 

  
 The Series established by the Original Series Consent is designated as the “4.125% Notes Due 2011.” 
  

	 	2.	Aggregate Principal Amount: 

  
 The 2011 Series is not limited as to the aggregate principal amount of all the promissory notes of the 2011 Series that the Company may issue. The Company
is issuing the Initial Notes, which have an aggregate original principal amount of $1,250,000,000. 
  

	 	3.	Maturity: 

  
 Final maturity of the Notes of the 2011 Series will be February 15, 2011. 
  

	 	4.	Interest: 

  

	 	a.	Rate 

  
 The Notes will bear interest at the per annum rate of 4.125%, which interest shall commence accruing from and including February 18, 2004. Additional
Amounts (as defined in Section 4(a) of the Form of Note), if any, will also be payable on the Notes. 
  

	 	b.	Payment Dates 

  
 Interest will be payable on the Notes semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2004, to the person or
persons in whose name or names the Notes are registered at the close of business on the preceding February 1 or August 1, as the case may be. Interest on the Notes will be computed on the basis of a 360-day year of twelve 30-day months. 

 

	 	5.	Currency of Payment: 

  
 The principal and interest payable with respect to the Notes shall be payable in United States dollars. 
  

	 	6.	Payment Places: 

  
 All payments of principal of and interest on the Notes will be made to The Depository Trust Company so long as the Notes are in global form, otherwise
payment shall be made at the office or 

  

 2 

 
agency of the Company in the Borough of Manhattan, The City of New York. 
  

	 	7.	Optional Redemption Features: 

  
 The Company may redeem the Notes upon the occurrence of certain tax events pursuant to Section 4(b) of the Form of Note. 
  
 There is no sinking fund with respect to the Notes. 
  

	 	8.	Special Redemption Features, etc.: 

  
 None. 
  

	 	9.	Denominations: 

  
 $2,000 and integral multiples of $1,000 for the Notes. 
  

	 	10.	Principal Repayment: 

  
 100% of the principal amount of each Note. 
  

	 	11.	Registrar and Paying Agent: 

  
 J.P. Morgan Trust Company, National Association will be the registrar and paying agent for the Notes. 
  

	 	12.	Defeasance: 

  
 Sections 11.02, 11.03 and 11.04 of the Indenture apply to the Notes. 
  

	 	13.	Payment of Additional Amounts: 

  
 The Company shall pay additional amounts as set forth under Section 4 of the Form of Notes. 
  

	 	14.	Book-Entry Procedures: 

  
 The Notes shall be issued in the form of global Notes registered in the name of CEDE & Co. as nominee of The Depository Trust Company and will be
issued in certificated form only in limited circumstances, in each case, as set forth under Sections 11 and 12 of the Form of Notes. 
  

	 	15.	Other Terms: 

  
 Sections 2, 3, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17 of the Form of Note attached hereto as Annex B shall also apply to the Notes. 
  

 3 

 The Notes will not have any terms or conditions of the type contemplated by clause (iii), (vi), (vii),
(xii), (xiii), (xiv), (xv), (xvi) (xvii), or (xx) of Section 3.01 of the Indenture. 
  
 E. The Notes will be issued pursuant to and governed by the Indenture. To the extent that the Indenture’s terms apply to the Notes specifically or apply to the terms of all Securities of all Series established
pursuant to and governed by the Indenture, such terms shall apply to the Notes. 
  

 4 

 IN WITNESS WHEREOF, the undersigned has hereunto executed this Certificate as of February 10, 2004.

  

	
	
	 /s/ Joseph J. Fitzsimmons

	

	 Joseph J. Fitzsimmons

	Senior Vice President of Finance and Treasurer

  

	
	ATTEST:
	
	 /s/ Anthony D. George

	

	Anthony D. George
	 Assistant General Counsel, Finance
and Assistant Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]